The goal of this prospective observational pilot study is to evaluate the tolerability and
safety of RESTASIS (cyclosporine ophthalmic solution 0.05%) when added to the PROSE
(Prosthetic Replacement of the Ocular Surface Ecosystem) lens reservoir in patients with
ocular surface disease (OSD).